|
|
 |
|
Total Number of Holdings (excluding cash): 50
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
68,808 |
$97,087,399.92 |
8.25% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
310,410 |
$89,658,824.40 |
7.61% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
2,796,755 |
$85,776,475.85 |
7.29% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
299,412 |
$81,008,910.72 |
6.88% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
538,680 |
$79,918,564.80 |
6.79% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
49,810 |
$47,880,360.60 |
4.07% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
271,946 |
$46,320,562.18 |
3.93% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
183,696 |
$45,742,140.96 |
3.88% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
2,410,534 |
$45,004,669.78 |
3.82% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
92,570 |
$43,086,706.50 |
3.66% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
516,180 |
$42,935,852.40 |
3.65% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
69,224 |
$41,266,503.12 |
3.50% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
73,085 |
$40,426,967.75 |
3.43% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
319,384 |
$38,338,855.36 |
3.26% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
595,681 |
$37,539,816.62 |
3.19% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
443,331 |
$31,090,803.03 |
2.64% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
126,533 |
$27,133,736.52 |
2.30% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
91,913 |
$20,825,647.54 |
1.77% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
159,787 |
$20,604,533.65 |
1.75% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
27,418 |
$17,770,702.52 |
1.51% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
570,881 |
$13,758,232.10 |
1.17% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
94,032 |
$13,667,551.20 |
1.16% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
233,064 |
$13,387,196.16 |
1.14% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
38,508 |
$13,036,498.32 |
1.11% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
57,003 |
$9,006,474.00 |
0.76% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
39,409 |
$8,702,689.47 |
0.74% |
| Caris Life Sciences, Inc. |
CAI |
142152107 |
Biotechnology |
217,020 |
$6,966,342.00 |
0.59% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
316,661 |
$6,472,550.84 |
0.55% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
101,884 |
$6,107,945.80 |
0.52% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
19,466 |
$5,976,451.32 |
0.51% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
34,792 |
$5,940,038.16 |
0.50% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
46,567 |
$5,937,758.17 |
0.50% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
61,920 |
$5,913,979.20 |
0.50% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
159,688 |
$5,731,202.32 |
0.49% |
| Oruka Therapeutics, Inc. |
ORKA |
687604108 |
Biotechnology |
59,722 |
$5,699,270.46 |
0.48% |
| Adaptive Biotechnologies Corporation |
ADPT |
00650F109 |
Biotechnology |
221,977 |
$5,562,743.62 |
0.47% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
88,582 |
$5,459,308.66 |
0.46% |
| Iovance Biotherapeutics, Inc. |
IOVA |
462260100 |
Biotechnology |
677,104 |
$5,430,374.08 |
0.46% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
117,720 |
$5,284,450.80 |
0.45% |
| Tango Therapeutics, Inc. |
TNGX |
87583X109 |
Biotechnology |
242,202 |
$5,270,315.52 |
0.45% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
37,447 |
$5,218,988.39 |
0.44% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
39,795 |
$5,135,146.80 |
0.44% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
15,401 |
$4,557,155.90 |
0.39% |
| Dianthus Therapeutics, Inc. |
DNTH |
252828108 |
Biotechnology |
52,392 |
$4,309,242.00 |
0.37% |
| Enliven Therapeutics Inc. |
ELVN |
29337E102 |
Biotechnology |
95,559 |
$4,264,798.17 |
0.36% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
83,453 |
$4,110,894.78 |
0.35% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
67,142 |
$3,999,648.94 |
0.34% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
191,341 |
$3,916,750.27 |
0.33% |
| Corcept Therapeutics Inc. |
CORT |
218352102 |
Pharmaceuticals |
48,806 |
$3,926,930.76 |
0.33% |
| Liquidia Technologies, Inc. |
LQDA |
53635D202 |
Biotechnology |
81,146 |
$3,395,960.10 |
0.29% |
| US Dollar |
$USD |
|
Other |
1,841,440 |
$1,841,439.57 |
0.16% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|